Current Approach to Screening for Lung Cancer. James R Jett M.D.
|
|
- Benjamin Reynolds
- 5 years ago
- Views:
Transcription
1 Current Approach to Screening for Lung Cancer James R Jett M.D.
2 Potential Conflicts of Interest I am Chief Medical Officer for Oncimmune Ltd (Biomarkers of Cancer) Co-Editor of Lung Cancer Section of UP-TO-DATE
3 Trends in Mortality USA: JAMA 2015;314: Reduction All Cause* 1, % Stroke % Heart Disease % Unintentional Injuries % Cancer % Diabetes % *Age-standardized death rate per 100,000
4 Mortality Trends: Six Leading Causes of Death USA COPD Mortality Increased by 100% 21 (1969) to 42 (2013) Rates decreased since 1999 (APC 0.3%) COPD Is The Third Most Common Cause of Death in the USA JAMA 2015;314:
5
6 Deaths Due to Cigarette Smoking (2011) for 12 Smoking-Related Cancers in USA Total Deaths Smoking Attributed Percent Larynx 3,728 2,856 77% Lung 156, ,799 80% Oral Cavity & Pharynx 8,576 4,032 47% Esophagus 14,404 7,307 51% Urinary Bladder 14,997 6,724 45% Total (all 12 cancers) 345, ,805 48% Amer Can Society JAMA, pub online June 15, 2015
7 Cancer Statistics 2015 Lung Cancer New Cases Deaths (no.) Cancer Deaths (%) Men 115,610 86, Women 105,590 (48%) Total 221, ,050 71, American Cancer Society, Cancer Statistics; 2015
8 CP
9 Cancer Statistics 2015 k k k k k
10 Cancer Statistics 2015 Primary Site New Cases (no.) Deaths (no.) 5-Year Survival Lung 221, , Colorectal 132,700 49, Breast 234,190 40, Pancreas 48,960 40, Prostate 220,800 27, >99 American Cancer Society, Cancer Statistics; 2015
11 Lung Cancer 228,000 new cases in % will be dead within one year Symptomatic lung cancer is advanced stage disease and not curable
12 Lobar Collapse
13 Lung Cancer at Diagnosis: ,000 new cases Localized 15% Regional 22% Distant 56% Wender et al CA Cancer J Clin 2013
14 Where were We? Screening for Lung Cancer American Cancer Society, NCI, American College of Radiology, US Preventive Service Task Force CP
15 Lung Cancer Risk Predictions: PLCO Incidence Rate of Lung Cancer: per 10,000 Person Years on Control Arm (Intervention) Never Smoker: 2.5 (3.3) Former Smoker: 18.7 (19.3) Current Smoker: 71.4 (79.9) Tammemagi et al. JNCI 2011; 103:
16 CP
17 CP
18 National Lung Cancer Screening Trial (NLST) Smoker Former smoker 30 pk yr Age ,000 PLCO 10,000 ACRIN Randomized Low-dose fast spiral CT CXR Years CP
19 Lung Cancer Mortality: October 2010 ARM Lung Cancer Deaths Lung Cancer Mortality per 100,000 PY Reduction in Lung Cancer Mortality LDCT % CXR
20 Cancers Detected by Round of NLST LDCT CXR T T T
21 True and False Positive Screens Low Dose CT Screen Results T0 T1 T2 Total Positive 7,193 6,902 4,052 Lung Cancer 270 (4%) 168 (2%) 211 (5%) No Lung Cancer 96% 98% 95%
22 Results by Round of Screening NLST LDCT T0 (%) T1(%) T2 (%) Cancers (N) Sensitivity Specificity PPV NPV
23 Predictive Value of LDCT Nodule Size PPV% 4mm mm mm mm mm 29.7 >30mm 41.3 Hilar or Mediastinal Adenopathy 18.5 Negative Predictive Value 99.9% NLST Team. NEJM 2013; 368:
24 Two-Year Probability of Lung Cancer by Nodule Size: NELSON 2-Year Size in mm Probability <4 0.6% 5 to <6 0.9% 6 to <7 0.4% 7 to <8 1.8% P=< to <10 2.9% P=<.001 Horewig et al. Lancet Oncol 2014; Pub online Oct 2
25 Two-Year Probability of Lung Cancer by Nodule Size: NELSON 2-Year Size in mm Probability 8 to <10 2.9% 10 to < % 15 to < % 20 to < % % Horewig et al. Lancet Oncol 2014; Pub online Oct 2
26 CP
27 Results of Initial LDCT Screening for Lung Cancer LDCT CXR Lung Cancer (N) 292 (1.1%) 190 (0.7%) Stage I 158 (54%) 170 (37%) Stage IIB/IV 120 (41%) 112 (59%) NLST Team. NEJM 2013; 368:
28 Lung Cancer Stage I NELSON 64% (N Eng J Med) NLST 63%
29
30 Lung Cancer Detection Cumulative by Year Years Cancer (CT) (649) 78 (279) 5 approx (900) approx (600) 7 (1060) (941) Cancer (CXR) N Eng J Med 2011; 365:
31 NLST Lung Cancer Stages LDCT 1 st 3 Years Overall Stage IA/B 63% 50% Stage III B/IV 21% 31% N Eng J Med 2011; 365:
32 NELSON: LDCT Screening Test Performance Screen Detected Cancers Stage III/IV 22% (44/196) Small Cell 4% (8/196) Adenocarcinoma 52% (102/196) Interval Cancers 83% (29/35) 20% (7/35) 26% (9/35) Horewig et al. Lancet Oncology 2014; 15:
33 National Lung Cancer Screening Trial 20% Mortality Reduction from Lung Cancer 6.7% All Cause Mortality Reduction 320 Persons Needed to be Screened with LDCT to Prevent One Death NNS to prevent one death was 219 NEJM 2011; 365: AIM 2013; pub 30 July
34 Cost Effectiveness of CT Screening: National Lung Cancer Screening Trial Cost Per Life Year: ICER $52,000 (30k - 106k) Cost per QALF $81,000 (52k - 186k) Black et al. New Eng J Med 2014; 371:
35 NLST Incremental Costs for High-Risk Groups: QALY Overall Study Age: Age: Current Smoker Risk Group: 4 th Quintile Risk Group: 5 th Quintile 81k 48k 54k 43k 32k 52k Black et al. New Eng J Med 2014; 371:
36 Number Need to Screen to Prevent One Death Mammogram Age 40-49: 1,904 Age 50-59: 1,339 Age 60-79: 337 Fecal Occult Blood (5 years): 1,374 Flex Sigmoidoscopy: 871 (PLCO: NEJM 2012; 336:2345) PSA: 1,410 Treat 48 to Prevent One Death
37 Pan-Canada CT Screening Trial Cost Analysis from Canadian Public Payer s Perspective for Resources Used in Screening and Treatment of Lung Cancer Participants Had a 2% or Greater Risk Over Three Years Average Cost per Screened Individual With LDCT Was $453 for Initial 18 Months o Costs Dependent on Detected Nodule Size Cressman et al. J Thorac Oncol 2014;9:
38 Pan-Canada CT Screening Trial Mean Cost of $33,344 Over Two Years for Curative Surgery Cost of Treating Advanced Disease: $47,792 Cressman et al. J Thorac Oncol 2014;9:
39 NLST and Smoking Cessation 48% of Participants Were Current Smokers o NELSON Trial 47% Current Smokers 23.5% of Smokers in NLST With Normal Results Quit Smoking After Three Years Smoking Cessation Was Associated With Screen-Detected Abnormalities Quit Rate Was Highest if Screening Study Was Suspicious for Lung Cancer and Was New or Changed From Previous Screen (OR=0.66) Tammemagi et al. JNCI 2014;dju 084, June 11
40 NLST and Smoking Cessation Odds Ratio of Cessation Normal Screen 1 Suspicious Minor Abnormality Major Abnormality (Not Suspicious) Stable Suspicious Abnormality New Unstable Suspicious (32% Quit) 0.91 (P=.005) 0.81 (P<.001) 0.78 (P<.001) 0.66 (P<.001) Tammemagi et al. JNCI 2014;dju 084, June 11
41 Annual Number of Lung Cancer Deaths Averted Approximately 8.6 million Americans met the NLST criteria for screening in 2010 If CT screening was fully adopted A total of 12,000 lung cancer deaths would be averted each year Ma et al Cancer 2013;119:1381-5
42 USA Population Covered by the NLST Criteria NLST criteria would detect 26.7% of all lung cancers NLST criteria covers 6.2% of the population > age 40 Pinsky and Berg, J Med Screen 2012; 19:
43 Lung Cancer Risk Prediction: PLCO Model Age Education Body Mass Index Family History Lung Cancer History of COPD Race Smoking Status (NS, F, C) Smoking Intensity Smoking Duration Quit Time in Former Smokers Tammemagi et al. NEJM 2013;368:728
44 Spread sheet calculator of Lung Cancer risk and Lung Nodule Risk: Available online
45 Screening and Risk Selection Criteria NLST and PLCOm2012 Six-Year Risk Models Applied to CXR Intervention Arm of PLCO PLCOm2012 Risk of 1.5% was at 65 Percentile of Risk in NLST At risk of 1.5% the lung cancer mortality of CT screening was consistently below the CXR rates Tammemagi et al. PLOS 2014; 11:e
46 Screening and Risk Selection Criteria If PLCOm2012 Risk of 1.5%, as Compared to NLST Criteria, Were Applied to PLCO Intervention Arm (Smokers) 8.8% fewer were selected for screening 12.4% more lung cancers detected Sensitivity increased 80% vs 71% Specificity similar 66% vs 63% Tammemagi et al. PLOS 2014; 11:e
47 Screening and Risk Selection Criteria At PLCOm2012 Risk 1.5% the Number Needed to Screen Was 255 (320 in NLST) In percentile the NNS was % of NLST Screenees Had Risk of <1.5% Tammemagi et al. PLOS 2014; 11:e
48 Screening and Risk Prediction Criteria None of the Never Smokers In The PLCO Intervention Arm Had a Risk of > 1.5% Do Not Screen Never Smokers!!! Tammemagi et al. PLOS 2014;11ie
49 Airflow Limitation and Histology Shift in NLST Cohort w/spirometry Lung Cancer Cases N 18, All COPD 34% 52% No COPD 64% 46% Young, et al. AJRCCM 2015;192:
50 Airflow Limitation and Histology Shift in NLST Two-Fold Increase in Lung Cancer Incidence with COPD Rate ratio 2.15 (P <0.001) COPD Was Also Associated with Significantly Fewer BAC-Related Cancers In Patients with Lung Cancer and No COPD, There Were an Additional 29 Cancers in the CT Arm vs CXR Arm Excess of 30 BAC in the CT Arm Young, et al. AJRCCM 2015;192:
51 Screening for Lung Cancer: US Preventive Services Task Force USPSTF recommends annual screening for lung cancer with LDCT in adults aged 55-80years 30 pack year smoking history and currently smoke or have quit within the past 15 years
52 Screening for Lung Cancer: US Preventive Services Task Force Screening should be discontinued once a person has not smoked for 15 years or develops a health problem that substantially limits life expectancy or the ability or willingness to have curative surgery. Grade B Recommendation
53 Smoking Cessation and Screening Modeling Data Estimated That Offering Smoking Cessation With Annual Screening Exams Will Improve Cost Effectiveness By: 20-45% Villanti, et al. PloS one 2013; 8:e71379
54 Teachable Moment An Event or Situation in Which There is Increased Capacity or Desire to Change Screening with LDCT is Thought to Be a Teachable Moment for Smoking Cessation
55 Smoking Abstinence & Lung Cancer Specific Mortality Secondary analysis of the NLST Current smokers had an increased lung cancer specific : (HR ) & all cause mortality (HR ) Former smokers in CXR arm that were abstinent for 7 years had 20% mortality reduction. Tanner et al AJRCCM 2015; Pub Online 26 Oct
56 Smoking Abstinence & Lung Cancer Mortality Tanner et al AJRCCM 2015; Pub Online 26 Oct
57 Smoking Abstinence & Lung Cancer Specific Mortality Maximum benefit was seen with smoking abstinence and LDCT screening at 15 years HR 0.62 ( ) 38% risk reduction in lung cancer specific mortality Tanner et al AJRCCM 2015; Pub Online 26 Oct
58 Category Descriptor ACR LungRADS Category Descriptor Primary Category Incomplete - 0 Negative No nodules & definitely benign nodules 1 Benign Appearance or Behavior Nodules with a very low likelihood of becoming a clinically active cancer due to size or lack of growth 2 Probably benign Suspicious Probably benign finding(s) - short term follow up suggested; includes nodules with a low likelihood of becoming a clinically active cancer Findings for which additional diagnostic testing and/or tissue sampling is recommended 3 4A 4B
59 ACR LungRADS Category Category Descriptor Categor y Findings Management Negative Benign Appearanc e or Behavior No nodules and definitely benign nodules Nodules with a very low likelihood of becoming a clinically active cancer due to size or lack of growth 1 2 no lung nodules nodule(s) with specific calcifications: complete, central, popcorn, concentric rings and fat containing nodules solid nodule(s): < 6 mm new < 4 mm part solid nodule(s): < 6 mm total diameter on baseline screening non solid nodule(s) (GGN): < 20 mm OR 20 mm and unchanged or slowly growing category 3 or 4 nodules unchanged for 3 months Continue annual screening with LDCT in 12 months
60 ACR LungRADS Category Category Descriptor Category Findings Management solid nodule(s): Probably Benign Probably benign finding(s) - short term follow up suggested; includes nodules with a low likelihood of becoming a clinically active cancer 3 OR 6 to < 8 mm at baseline new 4 mm to < 6 mm part solid nodule(s) 6 mm total diameter with solid component < 6 mm OR new < 6 mm total diameter 6 month LDCT non solid nodule(s) (GGN) 20 mm on baseline CT or new
61 ACR LungRADS Category Category Descriptor Category Findings Management Suspiciou s Findings for which additional diagnostic testing and/or tissue sampling is recommended 4A 4B 4X solid nodule(s): 8 to < 15 mm at baseline OR growing < 8 mm OR new 6 to < 8 mm part solid nodule(s: 6 mm with solid component 6 mm to < 8 mm OR with a new or growing < 4 mm solid component endobronchial nodule solid nodule(s) 15 mm OR new or growing, and 8 mm part solid nodule(s) with: a solid component 8 mm OR a new or growing 4 mm solid component Category 3 or 4 nodules with additional features or imaging findings that increases the suspicion of malignancy 3 month LDCT; PET/CT may be used when there is a 8 mm solid component chest CT with or without contrast, PET/CT and/or tissue sampling depending on the *probability of malignancy and comorbidities. PET/CT may be used when there is a 8 mm solid component.
62 Lung-RADS in National Lung Screening Trial BASELINE Lung RADS (%) NLST (%) Sensitivity False Positive PPV NPV Pinsky et al. Ann Int Med, pubonline February 10, 2015
63 Lung-RADS in National Lung Screening Trial AFTER BASELINE Lung-RADS (%) NLST (%) Sensitivity False Positive PPV NPV Pinsky et al. Ann Int Med, pubonline February 10, 2015
64 Lung-RADS in National Lung Screening Trial 25 Missed Cancers at Baseline 12 were GGN < 20mm 13 had solid or part-solid nodule < 6mm 61 Missed Cancers on Subsequent Screening 26 were GGN < 20mm 35 had solid or part-solid pre-existing but non-growing nodules Pinsky et al. Ann Int Med, pubonline February 10, 2015
65 True and False Positive Results & Diagnostic Procedures Missed with Lung-RADS Baseline (%) After Baseline (%) All Missed Cancers 25 (9) 61 (16) 86 (13) False Positive Avoided 3,618 (52) 7,997 (76) 11,615 (66) Invasive Procedures 60 (23) 57 (23) 117 (23) Chest CT Avoided 3,557 (50) 2,150 (45) 5,707 (48) Pinsky et al. Ann Int Med, pubonline February 10, 2015
66 Components Necessary for High Quality Lung Cancer Screening Policy Statement of ACCP & ATS Mazzone et al Chest 2014 doi /chest
67 Components Necessary for High Quality Lung Cancer Screening Who is offered screening How often and for how long How the CT is performed Lung Nodule identification Structured reporting Nodule management algorithms Smoking cessation Patient and Provider education
68 February 5th, 2015 CMS issues final approval for Lung Cancer Screening Lengthy report with details on approved screening program and center requirements
69 Must collect and submit data to CMS Data Type Facility Radiologist Patient Ordering practitioner Demographics Indication Smoking history Scanner/radiation dose 4 more items on outcomes Minimum data elements Identifier NPI Identifier NPI DOB, gender, race/ethnicity LC screening; no symptoms Current, former, yrs quit Manufacture/model/dose
70 CP
71 Risk Calculator for Radiation Exposure r/calculator-normal-studies.php.
SCBT-MR 2015 LungRADS : Basics
SCBT-MR 2015 LungRADS : Basics Reginald F. Munden MD, DMD, MBA I have no conflicts of interest to report National Lung Cancer Screening Trial 20% lung cancer mortality reduction 6.9% all cause mortality
More informationScreening Programs background and clinical implementation. Denise R. Aberle, MD Professor of Radiology and Engineering
Screening Programs background and clinical implementation Denise R. Aberle, MD Professor of Radiology and Engineering disclosures I have no disclosures. I have no conflicts of interest relevant to this
More informationSCBT-MR 2016 Lung Cancer Screening in Practice: State of the Art
SCBT-MR 2016 Lung Cancer Screening in Practice: State of the Art Reginald F. Munden MD, DMD, MBA I have no conflicts of interest to report National Lung Cancer Screening Trial 20% lung cancer mortality
More informationLearning Objectives. 1. Identify which patients meet criteria for annual lung cancer screening
Disclosure I, Taylor Rowlett, DO NOT have a financial interest /arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict of interest in the context
More informationAnn Intern Med. 2012;156(5):
Lung Cancer Screening Update Doug Arenberg, M.D. University of Michigan Outline Screening; Some simple but necessary truths Do people benefit from screening? What are the harms (and are they outweighed
More informationChristine Argento, MD Interventional Pulmonology Emory University
Christine Argento, MD Interventional Pulmonology Emory University Outline Lung Cancer Statistics Prior Studies for Lung Cancer Screening NLST Studies Following NLST Future Directions Lung Cancer American
More informationDisclosures. Overview. Selection the most accurate statement: Updates in Lung Cancer Screening 5/26/17. No Financial Disclosures
Updates in Lung Cancer Screening Disclosures No Financial Disclosures Neil Trivedi, MD Associate Professor of Clinical Medicine SF VAMC Pulmonary and Critical Care Director, Bronchoscopy & Interventional
More informationLung Cancer Screening: Now What?
Lung Cancer Screening: Now What? Gerold Bepler, M.D., Ph.D. Director, President & CEO Michigan Cancer Consortium, 2013 Annual Meeting, Lansing, MI, 11/20/13 Lung Cancer #1 Cause of Cancer Death for & *
More informationDISCLOSURE. Lung Cancer Screening: The End of the Beginning. Learning Objectives. Relevant Financial Relationship(s) Off Label Usage
Peninsula Regional Medical Center 12 th Annual Lung Cancer Conference March 9, 2017 Lung Cancer Screening: The End of the Beginning David E. Midthun M.D. Professor of Medicine College of Medicine, Mayo
More informationGoals of Presentation
Goals of Presentation Review context of lung cancer screening why is it important? Review data from NLST supporting screening with lowdose CT (LDCT) scanning Discuss the pros and cons of LDCT screening
More informationLung Cancer Screening: Evidence and current recommendations
Lung Cancer Screening: Evidence and current recommendations 20 th March 2018 Dr Annette McWilliams Fiona Stanley Hospital University of Western Australia WA Cancer & Palliative Care Network I have no financial
More informationLung Cancer Screening: Benefits and limitations to its Implementation
Lung Cancer Screening: Benefits and limitations to its Implementation Rolando Sanchez, MD Clinical Assistant Professor Pulmonary-Critical Care Medicine University of Iowa Lung cancer - Epidemiology Cancer
More informationLUNG CANCER SCREENING: ON WHOM DID YOU DO IT AND ON WHOM DO YOU RESPOND TO THE RESULTS?
LUNG CANCER SCREENING: ON WHOM DID YOU DO IT AND ON WHOM DO YOU RESPOND TO THE RESULTS? DAVID O. WILSON, MD, MHP DIRECTOR GEORGIA COOPER MEMORIAL LUNG CANCER RESEARCH REGISTRY UNIVERSITY OF PITTSBURGH
More informationSCBT-MR 2015 Incidentaloma on Chest CT
SCBT-MR 2015 Incidentaloma on Chest CT Reginald F. Munden MD, DMD, MBA I have no conflicts of interest to report Incidentaloma Pulmonary Nodule Mediastinal Lymph Node Coronary Artery Calcium Incidental
More informationCLINICAL GUIDELINES. Lung-Cancer Screening Program Guidelines Robert Y. Kanterman, M.D. and Thomas J. Gilbert, M.D., M.P.P.
CLINICAL GUIDELINES Lung-Cancer Screening Program Guidelines Robert Y. Kanterman, M.D. and Thomas J. Gilbert, M.D., M.P.P. 3/14/2015 Introduction: The purpose of a lung-cancer screening program is to detect
More informationVHA Demonstration Project for Lung Cancer Screening Using Low-Dose Chest CT Screening
VHA Demonstration Project for Lung Cancer Screening Using Low-Dose Chest CT Screening ATS San Francisco 2016 James K. Brown MD 1, Kathryn L. Rice, MD 2 (1) San Francisco VA (2) Minneapolis VAMC Disclosures
More informationA Comprehensive Cancer Center Designated by the National Cancer Institute
N C I C C C A Comprehensive Cancer Center Designated by the National Cancer Institute Screening and Early Detection of Lung Cancer: Ready for Practice? David S. Ettinger, MD, FACP, FCCP Alex Grass Professor
More informationSelected Controversies. Cancer Screening. Breast Cancer Screening. Selected Controversies. Page 1. Using Best Evidence to Guide Practice
Cancer Screening Using Best Evidence to Guide Practice Judith M.E. Walsh, MD, MH Division of General Internal Medicine Women s Health Center of Excellence University of California, San Francisco Selected
More informationLung Cancer Screening: To screen or not to screen?
Lung Cancer Screening: To screen or not to screen? Dan J. Raz, M.D. Co Director, Lung Cancer Screening Program Co Director, LungCancer and Thoracic OncologyProgram Assistant Professor, Thoracic Surgery
More informationSHARED DECISION MAKING AND LUNG CANCER SCREENING
SHARED DECISION MAKING AND LUNG CANCER SCREENING DISCLOSURES Cathleen E. Morrow, MD None William C. Black, MD No financial disclosure Co-investigator for NLST Member of the ACR Lung-RADS Screening Registry
More informationPage 1. Cancer Screening for Women I have no conflicts of interest. Overview. Breast, Colon, and Lung Cancer. Jeffrey A.
Cancer Screening for Women 2017 Breast, Colon, and Lung Cancer Jeffrey A. Tice, MD Professor of Medicine Division of General Internal Medicine University of California, San Francisco I have no conflicts
More informationLung Cancer screening :
Lung Cancer screening : Pro-Contra SAMO interdisciplinary workshop on chest tumors 27 and 28 january 2017 Prof L.P.Nicod Sevice de pneumologie CHUV-Lausanne -CH Lung Cancer How big is the problem? Epidemiology
More informationLDCT Screening. Steven Kirtland, MD. Virginia Mason Medical Center February 27, 2015
LDCT Screening Steven Kirtland, MD Virginia Mason Medical Center February 27, 2015 2 Disclosures 4 5 Cancer Screening Mrs H 64yo 50 pk year smoker Lung Cancer Epidemiology Leading Cause of Cancer Death
More informationNational Lung Screening Trial Results
National Lung Screening Trial Results Ella A. Kazerooni, M.D. Professor & Director Cardiothoracic Radiology Associate Chair for Clinical Affairs University of Michigan NLST STOPPED! Lung cancer trial results
More informationPulmonologist s Perspective
Low-dose CT for lung cancer screening Pulmonologist s Perspective Literature Review Kang-Yun Lee, MD PhD Department of Thoracic Medicine Taipei Medical University- Shuang Ho Hospital Taiwan Local vs. Advanced
More informationThe Maine Lung Cancer Coalition. Working Together to Reduce Lung Cancer in Maine
The Maine Lung Cancer Coalition Working Together to Reduce Lung Cancer in Maine funding Maine Lung Cancer Coalition (MLCC) Webinar Lung Cancer Screening: Following Up On Abnormal Low Dose CT Scans with
More informationLung Cancer Screening:
Lung Cancer Screening: Maximizing Gain and Dealing with Pandora s Box Mark M. Fuster, MD Division of Pulmonary & Critical Care UCSD Department of Medicine & VA San Diego Healthcare Service San Diego, CA
More informationLung Cancer Screening. Eric S. Papierniak, DO NF/SG VHA UF Health
Lung Cancer Screening Eric S. Papierniak, DO NF/SG VHA UF Health Overview Background Supporting evidence Guidelines Practical considerations Patient selection What to do with abnormal results Billing/coding
More informationNone
2014 None rosemary clooney Cancer is one of the most common diseases in the developed world: 1 in 4 deaths are due to cancer 1 in 17 deaths are due to lung cancer Lung cancer is the most common
More informationLessons learned for the conduct of a successful screening trial
Lessons learned for the conduct of a successful screening trial Christine D. Berg, M.D. Adjunct Professor Department of Radiation Oncology Johns Hopkins Medicine IOM State of the Science in Ovarian Cancer
More informationA Summary from the 2013World Conference on Lung Cancer Sydney, Australia
A Summary from the 2013World Conference on Lung Cancer Sydney, Australia In 2011, the U.S. National Lung Screening Trial (NLST) has demonstrated that low-dose computed tomography (LDCT) screening of high
More informationLung cancer Screening
Lung cancer Screening Family Physicians and CancerControl 2018 Alain Tremblay Division of Respiratory Medicine University of Calgary Disclosures BD Inc - Consultant / Medical Device development Olympus
More informationLung Cancer Screening
Lung Cancer Screening Steven Leh, MD, FCCP Diplomat of the American Association for Bronchology and Interventional Pulmonology Aurora Medical Group Pulmonary and Sleep Medicine February 10, 2018 Disclosures
More informationLUNG CANCER SCREENING WHAT S THE IMPACT? Nitra Piyavisetpat, MD Department of Radiology Chulalongkorn University
LUNG CANCER SCREENING WHAT S THE IMPACT? Nitra Piyavisetpat, MD Department of Radiology Chulalongkorn University Objective LDCT lung cancer screening (LCS) Potential Benefits & Harms Recommendation of
More informationLUNG CANCER SCREENING: LUNG CANCER SCREENING: THE TIME HAS COME LUNG CANCER: A NATIONAL EPIDEMIC
: THE TIME HAS COME Physician Leader, Lung Cancer Multi-Disciplinary Program Fletcher Allen Health Care Annual Meeting Montpelier, VT - April 25, 2014 Gerald S. Davis, MD Professor of Medicine University
More informationScreening for Lung Cancer. Michael S. Nolledo, MD Deborah Heart and Lung Center
Screening for Lung Cancer Michael S. Nolledo, MD Deborah Heart and Lung Center 1 1 Outline Ø Introduction Ø Lung Cancer Screening pre-2010 Ø Lung Cancer Screening today 2 2 Lung Cancer 2011 (Siegel et
More informationRichard M. Hoffman, MD, MPH University of Iowa Carver College of Medicine Holden Comprehensive Cancer Center
Richard M. Hoffman, MD, MPH University of Iowa Carver College of Medicine Holden Comprehensive Cancer Center Consultant, Healthwise, developing cancer screening decision support tools Consultant, Agency
More informationCT screening for lung cancer. Should it be done in the Indian context?
CT screening for lung cancer Should it be done in the Indian context? Wilson and Jungner screening criteria 1. The condition sought should be an important health problem. 2. There should be an accepted
More informationLung Cancer Screening: To Screen or Not to Screen?
Lung Cancer Screening: To Screen or Not to Screen? Lorriana Leard, MD Co-Director of UCSF Lung Cancer Screening Program Vice Chief of Clinical Activities UCSF Pulmonary, Critical Care, Allergy & Sleep
More informationWhat to know and what to make of it
Lung Cancer Screening: What to know and what to make of it J. Matthew Reinersman, MD Assistant Professor of Surgery Division of Thoracic and Cardiovascular Surgery Department of Surgery University of Oklahoma
More informationScreening for Lung Cancer - State of the Art
Screening for Lung Cancer - State of the Art Rohit Kumar, MD Assistant Professor of Medicine Fox Chase Cancer Center Temple University School of Medicine Philadelphia, PA Objectives Review current evidence
More informationLung Cancer Screening. Ashish Maskey MD Interventional Pulmonology UK Health Care Dec 1 st 2017
Lung Cancer Screening Ashish Maskey MD Interventional Pulmonology UK Health Care Dec 1 st 2017 Nearly one in six American adults currently smoke cigarettes An estimated 40 million adults in the United
More informationLung Cancer Screening
Scan for mobile link. Lung Cancer Screening What is lung cancer screening? Screening examinations are tests performed to find disease before symptoms begin. The goal of screening is to detect disease at
More informationLung Cancer Screening: Who, What, Why? Myths Dispelled
Lung Cancer Screening: Who, What, Why? Myths Dispelled Presented By: MaryAnn Tateosian, RT (R), M, MM, CIIP MGH Lung Screening Program Manager December 11, 2018 1 Lung Screening Objectives History of Smoking
More informationOutcomes in the NLST. Health system infrastructure needs to implement screening
Outcomes in the NLST Health system infrastructure needs to implement screening Denise R. Aberle, MD Professor of Radiology and Bioengineering David Geffen School of Medicine at UCLA 1 Disclosures I have
More informationExample of lung screening
Justification of the use of CT for individual health assessment of asymptomatic people How to obtain evidence for IHA - Example of lung screening Mathias Prokop, MD PhD Professor of Radiology Radboud University
More informationCT Screening for Lung Cancer for High Risk Patients
CT Screening for Lung Cancer for High Risk Patients The recently published National Lung Cancer Screening Trial (NLST) showed that low-dose CT screening for lung cancer reduces mortality in high-risk patients
More informationObjectives. Why? Why? Background 11/5/ % incurable disease at presentation Locally advanced disease Metastasis. 14% 5 year survival
Objectives Appraise lung cancer screening trials results Review screening guidelines Lung Cancer Screening: Past, Present and Future Chi Wan Koo, MD Koo.chiwan@mayo.edu Discuss recommendations essential
More informationPage 1. Selected Controversies. Cancer Screening! Selected Controversies. Breast Cancer Screening. ! Using Best Evidence to Guide Practice!
Cancer Screening!! Using Best Evidence to Guide Practice! Judith M.E. Walsh, MD, MPH! Division of General Internal Medicine! Womenʼs Health Center of Excellence University of California, San Francisco!
More informationEquity Issues with Lung Cancer Screening Prevent Cancer - Quantitative Imaging Workshop November 5-6, 2018 Alexandria, VA
Equity Issues with Lung Cancer Screening Prevent Cancer - Quantitative Imaging Workshop November 5-6, 2018 Alexandria, VA Mary Pasquinelli, MS, APRN, FNP-BC Pulmonary and Thoracic Medical Oncology Director,
More informationCriteria USPSTF CMS. Frequency Annual screening Annual screening. No signs or symptoms of lung cancer
Lung Cancer Screening Guidelines with low- dose computed tomography (LDCT): USPSTF and CMS February 6, 2015 Kentucky Cancer Consortium and Kentucky LEADS Component 3 Jennifer Redmond Knight, DrPH, jredknight@kycancerc.org
More informationLung Cancer Screening
Scan for mobile link. Lung Cancer Screening What is lung cancer screening? Screening examinations are tests performed to find disease before symptoms begin. The goal of screening is to detect disease at
More informationApproach to Pulmonary Nodules
Approach to Pulmonary Nodules Edwin Jackson, Jr., DO Assistant Professor-Clinical Director, James Early Detection Clinic Department of Internal Medicine Division of Pulmonary, Allergy, Critical Care and
More informationCurrent Strategies in the Detection of Breast Cancer. Karla Kerlikowske, M.D. Professor of Medicine & Epidemiology and Biostatistics, UCSF
Current Strategies in the Detection of Breast Cancer Karla Kerlikowske, M.D. Professor of Medicine & Epidemiology and Biostatistics, UCSF Outline ν Screening Film Mammography ν Film ν Digital ν Screening
More informationLung Cancer Screening: Current Status
Lung Cancer Screening: Current Status I have no financial relationships, arrangements or affiliations and this presentation will not include discussion of investigational or off-label use of a product
More informationLUNG CANCER: LDCT DISCLOSURES NONE. Erika Swanson, MD Radiation Oncologist Ascension Columbia-St. Mary s February 1, /9/2018
LUNG CANCER: LDCT Erika Swanson, MD Radiation Oncologist Ascension Columbia-St. Mary s February 1, 2018 DISCLOSURES 2 NONE 1 OBJECTIVES 3 Rationale and evidence for LDCT for lung cancer screening Review
More informationPulmonary Nodules. Michael Morris, MD
Pulmonary Nodules Michael Morris, MD Case 45 year old healthy male Smokes socially Normal physical exam Pre-employment screening remote +PPD screening CXR nodular opacity Case 45 year old healthy male
More informationLung Cancer Screening Trials. Edward Harris Respiratory Research Fellow Sir Charles Gairdner Hospital
Lung Cancer Screening Trials Edward Harris Respiratory Research Fellow Sir Charles Gairdner Hospital Lung Cancer Screening in Australia Not Funded except as part of a clinical trial Rationale PLCO, ELCAP
More informationVeterans Health Administration Lung Cancer Screening Demonstration Project: Results & Lessons Learned
Veterans Health Administration Lung Cancer Screening Demonstration Project: Results & Lessons Learned Jane Kim, MD, MPH Acting Chief Consultant for Preventive Medicine National Center for Health Promotion
More informationLung Cancer Risk Associated With New Solid Nodules in the National Lung Screening Trial
Cardiopulmonary Imaging Original Research Pinsky et al. Lung Cancer Risk Associated With New Nodules Cardiopulmonary Imaging Original Research Paul F. Pinsky 1 David S. Gierada 2 P. Hrudaya Nath 3 Reginald
More informationPage 1. Controversies in Cancer Prevention and Screening. Disclosures. Screening. Principles of Screening. I have no conflicts of interest
Controversies in Cancer Prevention and Screening Disclosures Using the Best Evidence in 2015 I have no conflicts of interest Judith M.E. Walsh, MD, MPH Division of General Internal Medicine Women s Health
More informationScreening for Lung Cancer: New Guidelines, Old Problems
Screening for Lung Cancer: New Guidelines, Old Problems Robert Schilz DO, PhD Associate Professor of Medicine Interim Chief of the Division of Pulmonary, Critical Care and Sleep Medicine University Hospitals
More informationLUNG CANCER SCREENING
LUNG CANCER SCREENING Christopher Lettieri MD, FACP, FCCP, FAASM Pulmonary/Critical Care Consultant to the Surgeon General Professor of Medicine Walter Reed National Military Medical Center American College
More informationRole of CT in Lung Cancer Screening: 2010 Stuart S. Sagel, M.D.
Role of CT in Lung Cancer Screening: 2010 Stuart S. Sagel, M.D. Lung Cancer 219,440 new cases/year in U.S. (2009) 169,390 deaths/year in U.S. mortality greater than from breast, colon, prostate CA combined
More informationProfessor John K Field PhD, FRCPath University of Liverpool Cancer Research Centre, UK.
Professor John K Field PhD, FRCPath University of Liverpool Cancer Research Centre, UK. J.K.Field@liv.ac.uk 1.8 million new cases in 2012 Bender Nature Outlook 2014 Probability of survival: ALL participants
More informationUniversity of Connecticut. University of Connecticut Graduate School
University of Connecticut OpenCommons@UConn Master's Theses University of Connecticut Graduate School 5-7-2016 A Retrospective Study Assessing the Predictive Performance of a Lung Cancer Screening Risk
More informationPANEL DISCUSSION: SCREENING FOR LUNG CANCER. Anthony D Weaver MD
PANEL DISCUSSION: SCREENING FOR LUNG CANCER Anthony D Weaver MD Disclosures Anthony Weaver has no relationships to disclose. Thank God! A panel of experts! An Equal Opportunity University Objectives 1.
More informationLung cancer screening in Switzerland
SAMO Interdisciplinary Workshop on Chest Tumors 27 th and 28 th January 2017 Hotel Hermitage, Lucerne Lung cancer screening in Switzerland Walter Weder, MD, Professor of Surgery University Hospital Zurich,
More informationMEDICAL POLICY SUBJECT: LOW-DOSE COMPUTED TOMOGRAPHY (LDCT) FOR LUNG CANCER SCREENING. POLICY NUMBER: CATEGORY: Technology Assessment
MEDICAL POLICY SUBJECT: LOW-DOSE COMPUTED CANCER SCREENING 05/18/05, 03/16/06, 12/21/06, 08/16/07, PAGE: 1 OF: 6 If a product excludes coverage for a service, it is not covered, and medical policy criteria
More informationNew Advances in Lung Cancer
New Advances in Lung Cancer Douglas E. Wood, MD, FACS, FRCSEd (ad hom) Professor and Chief Division of Cardiothoracic Surgery Vice-Chair, Department of Surgery Endowed Chair in Lung Cancer Research University
More informationRobert J. McKenna M.D. Chief, Thoracic Surgery Cedars Sinai Medical Center
You Smoke, You Get Lung Cancer, You Die: Can Screening Change this Paradigm? Robert J. McKenna M.D. Chief, Thoracic Surgery Cedars Sinai Medical Center AATS Saturday 4/28/2012 Cancer Screening Cancer
More informationLung Cancer Screening Benefits, Risks & Challenges
Lung Cancer Screening Benefits, Risks & Challenges Polly Sather, APRN Yale Lung Screening and Nodule Program (Yale Lung SCAN) A Multidisciplinary Comprehensive Initiative Yale Cancer Center Thoracic Oncology
More informationLung Cancer Screening
Lung Cancer Screening Ravi Salgia, M.D., Ph.D. Professor and Chair Medical Oncology and Therapeutics Research City of Hope Nothing to disclose Disclosure Lung Cancer 2016 >200,000 cases projected >160,000
More informationPULMONARY NODULES DETECTED INCIDENTALLY OR BY SCREENING: LOTS OF GUIDELINES BUT WHERE IS THE EVIDENCE?
PULMONARY NODULES DETECTED INCIDENTALLY OR BY SCREENING: LOTS OF GUIDELINES BUT WHERE IS THE EVIDENCE? MICHAEL K. GOULD, MD SENIOR RESEARCH SCIENTIST DIRECTOR FOR HEALTH SCIENCES & IMPLEMENTATION SCIENCE
More informationEarly Detection of Lung Cancer. Amsterdam March 5 th 2010
Early Detection of Lung Cancer Amsterdam March 5 th 2010 Rob J van Klaveren, MD, PhD Dept. of Pulmonology Erasmus MC Rotterdam, the Netherlands Early Detection and Screening - Questions to be addressed
More informationLung Cancer Screening: Radiologic and Clinical Implications. Katherine R. Birchard, M.D. University of North Carolina at Chapel Hill
Lung Cancer Screening: Radiologic and Clinical Implications Katherine R. Birchard, M.D. University of North Carolina at Chapel Hill Nothing to disclose Objectives In context of NLST: Review Imaging Techniques
More informationCancer Screening I have no conflicts of interest. Principles of screening. Cancer in the World Page 1. Letting Evidence Be Our Guide
Cancer Screening 2012 Letting Evidence Be Our Guide Jeffrey A. Tice, MD Division of General Internal Medicine University of California, San Francisco I have no conflicts of interest Principles of screening
More informationNCCN Guidelines as a Model of Extended Criteria for Lung Cancer Screening
444 Original Research NCCN Guidelines as a Model of Extended Criteria for Lung Cancer Screening Brady J. McKee, MD; Shawn Regis, PhD; Andrea K. Borondy-Kitts, MS, MPH; Jeffrey A. Hashim, MD; Robert J.
More informationLung Cancer Diagnosis for Primary Care
Lung Cancer Diagnosis for Primary Care Daniel Nader, DO, FCCP Cancer Treatment Center of America Case 1 In which of the following situations would the U.S. Preventive Services Task Force (USPSTF) recommend
More informationCT Low Dose Lung Cancer Screening. Part I. Journey to LDCT LCS Program
CT Low Dose Lung Cancer Screening Part I Journey to LDCT LCS Program Paul Johnson, M.S., DABHP, DABR Cleveland Clinic September 26, 2015 Lung Caner is No. 1 In Cancer Related Death In The United States
More informationPULMONARY NODULES AND MASSES : DIAGNOSTIC APPROACH AND NEW MANAGEMENT GUIDELINES. https://tinyurl.com/hmpn2018
PULMONARY NODULES AND MASSES : DIAGNOSTIC APPROACH AND NEW MANAGEMENT GUIDELINES Heber MacMahon MB, BCh Department of Radiology The University of Chicago https://tinyurl.com/hmpn2018 Disclosures Consultant
More informationLung Cancer Screening In High Risk Populations:
Lung Cancer Screening In High Risk Populations: Michael Jaklitsch, M.D. Co-Chair of AATS Task Force on Lung Cancer Screening and Surveillance From the Brigham and Women s Hospital Harvard Medical School.
More informationLung Cancer Screening Computed Tomography Screening in Pa6ents at Risk for Lung Cancer
Lung Cancer Screening Computed Tomography Screening in Pa6ents at Risk for Lung Cancer Doug Arenberg, M.D. University of Michigan Disclosures Objec6ve Define patients who will benefit from screening for
More informationWill CT screening reduce overall lung cancer mortality? Associate Professor of Radiology Department of Medical Imaging UHN / MSH / WCH
Will CT screening reduce overall lung cancer mortality? Heidi Roberts MD FRCP(C) Heidi Roberts, MD, FRCP(C) Associate Professor of Radiology Department of Medical Imaging UHN / MSH / WCH Screening - Requirements
More informationCancer Screenings and Early Diagnostics
Cancer Screenings and Early Diagnostics Ankur R. Parikh, D.O. Medical Director, Center for Advanced Individual Medicine Hematologist/Medical Oncologist Atlantic Regional Osteopathic Convention April 6
More informationEpidemiology of Lung Cancer: Implications for screening and prevention
Epidemiology of Lung Cancer: Implications for screening and prevention Hormuzd A. Katki, Ph.D. Senior Investigator Division of Cancer Epidemiology and Genetics (DCEG) I thank my DCEG colleagues Neil Caporaso
More informationI appreciate the courtesy of Kusumoto at NCC for this presentation. What is Early Lung Cancers. Early Lung Cancers. Early Lung Cancers 18/10/55
I appreciate the courtesy of Kusumoto at NCC for this presentation. Dr. What is Early Lung Cancers DEATH Early period in its lifetime Curative period in its lifetime Early Lung Cancers Early Lung Cancers
More informationAn Update on Lung Cancer Screening Policy and the Role of Quitlines
An Update on Lung Cancer Screening Policy and the Role of Quitlines Robert J. Volk, PhD Vance Rabius, PhD The University of Texas MD Anderson Cancer Center North American Quitline Consortium NAQC Conference
More informationCancer Treatment Centers of America: Supercharge Your Knowledge: A Focus on Breast, Cervical and Prostate Screening Guidelines and Controversies
8 ACOFP 55th Annual Convention & Scientific Seminars Cancer Treatment Centers of America: Supercharge Your Knowledge: A Focus on Breast, Cervical and Prostate Screening Guidelines and Controversies Anthony
More informationCT Lung Screening Implementation Challenges: State Based Initiatives
CT Lung Screening Implementation Challenges: State Based Initiatives Andrea McKee, MD Chair Radiation Oncology Lahey Hospital and Medical Center Co-Director Rescue Lung, Rescue Life Program Co-Chair Massachusetts
More informationThe National Lung Screening Trial (NLST)
The National Lung Screening Trial (NLST) Pamela Marcus US National Cancer Institute May 21, 2012 Today s talk NLST: an overview Typical challenges in cancer screening RCTs Starting ti a trial in the presence
More informationUpdate in Breast Cancer Screening
Disclosure information: Update in Breast Cancer Screening Karla Kerlikowske, MDDis Update in Breast Cancer Screening Grant/Research support from: National Cancer Institute and Grail - and - Karla Kerlikowske,
More informationSHARED DECISION MAKING IN MEDICARE COVERAGE
SHARED DECISION MAKING IN MEDICARE COVERAGE Kate Goodrich, MD MHS Director, Center for Clinical Standards and Quality CMS April 2, 2016 Disclaimer: Views and comments in this presentation are those of
More informationSCREENING FOR EARLY LUNG CANCER. Pang Yong Kek
SCREENING FOR EARLY LUNG CANCER Pang Yong Kek Lecture Outline Why performing screening? How to improve early detection? Benefits and Risks of screening Challenges in screening Conclusion Why Performing
More information5/24/16. Current Issues in Breast Cancer Screening. Breast cancer screening guidelines. Outline
Disclosure information: An Evidence based Approach to Breast Cancer Karla Kerlikowske, MDDis Current Issues in Breast Cancer Screening Grant/Research support from: National Cancer Institute - and - Karla
More informationEpidemiology of Lung Cancer: Implications for screening and prevention
Epidemiology of Lung Cancer: Implications for screening and prevention Hormuzd A. Katki, Ph.D. Senior Investigator Division of Cancer Epidemiology and Genetics (DCEG) I thank my DCEG colleagues Neil Caporaso
More informationIEHP UM Subcommittee Approved Authorization Guidelines CT Screening (Low Dose) for Lung Cancer
CT Screening (Low Dose) for Lung Cancer Policy: There is currently adequate evidence that using low dose computed tomography (LDCT) to screen asymptomatic individuals who are at risk for lung cancer improves
More informationDOH LUNG CANCER SCREENING SERVICE SPECIFICATIONS
DOH LUNG CANCER SCREENING SERVICE SPECIFICATIONS December 2018 Page 1 of 18 Document Title: Document Ref. Number: DOH Lung Cancer Screening Service Specifications PH/NCD/LCSC/SR/0.9 Version: 0.9 Approval
More informationLung Cancer Screening
Lung Cancer Screening Preston Wright, DO University of Kansas School of Medicine- Wichita Family Medicine Residency at Via Christi Hospitals 1 Objectives Identify patients who need screened for lung cancer
More informationUpdates In Cancer Screening: Navigating a Changing Landscape
Updates In Cancer Screening: Navigating a Changing Landscape Niharika Dixit, MD I have no conflict of interest. 1 Why Should You Care Trends in Cancer Incidence by Site United States. Siegal Et al: CA
More information